ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.

TBPH Theravance Biopharma Inc

8.55
-0.43 (-4.79%)
After Hours
Last Updated: 16:16:15
Delayed by 15 minutes

Period:

Draw Mode:

Volume 370,830
Bid Price 8.56
Ask Price 8.95
News -
Day High 9.215

Low
8.21

52 Week Range

High
11.71

Day Low 8.52
Share Name Share Symbol Market Stock Type
Theravance Biopharma Inc TBPH NASDAQ Common Stock
  Price Change Price Change % Share Price Last Trade
-0.43 -4.79% 8.55 16:16:15
Open Price Low Price High Price Close Price Previous Close
8.99 8.52 9.215 8.55 8.98
Trades Shares Traded VWAP Financial Volume Average Volume 52 Week Range
5,019 370,830 US$ 8.63 US$ 3,201,886 - 8.21 - 11.71
Last Trade Type Quantity Price Currency
16:15:01 43 US$ 8.55 USD

Theravance Biopharma Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
412.29M 48.16M - 57.42M -55.19M -1.15 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

Theravance Biopharma News

Date Time Source News Article
5/22/202417:08Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of..
5/22/202417:06Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of..
5/22/202417:04Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of..
5/22/202417:02Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of..
5/15/202405:26Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]
5/13/202415:13Edgar (US Regulatory)Form 8-K - Current report
5/13/202415:05PR Newswire (US)Theravance Biopharma, Inc. Reports First Quarter 2024..
5/10/202417:10Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of..
5/10/202417:06Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of..
5/10/202417:04Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of..
5/10/202417:01Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of..
5/09/202415:15Edgar (US Regulatory)Form 8-K - Current report
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No TBPH Message Board. Create One! See More Posts on TBPH Message Board See More Message Board Posts

Historical TBPH Price Data

Period † Open High Low VWAP Avg. Daily Vol Change %
1 Week9.719.758.529.23334,082-1.16-11.95%
1 Month9.1410.378.409.20421,708-0.59-6.46%
3 Months9.5210.448.409.14401,399-0.97-10.19%
6 Months10.3611.718.219.65396,188-1.81-17.47%
1 Year10.9411.718.219.80426,355-2.39-21.85%
3 Years17.5318.836.109.84694,387-8.98-51.23%
5 Years18.9531.546.1012.53550,160-10.40-54.88%

Theravance Biopharma Description

Theravance Biopharma Inc is a diversified biopharmaceutical company focused on the discovery, development, and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused on the areas of inflammation and immunology. The firm applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. It develops lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).

Your Recent History

Delayed Upgrade Clock